GenSight Biologics announces publication of positive safety data from Phase I/II trial of GS010 in the JAMA Ophthalmology

GenSight Biologics reports topline results at Week 48 of the RESCUE Phase III clinical trial of GS010 in subjects within six months of visual loss onset due to Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics Updates its 2019 Financial Calendar

GenSight Biologics Announces its 2019 Financial Calendar

GenSight Biologics Reports its Cash Position as of December 31, 2018

GenSight Biologics reports sustained quality of life improvements at Week 72 of Phase III REVERSE clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics enrolls first subject in first-in-man PIONEER Phase I/II clinical trial of GS030 combining gene therapy and Optogenetics for the treatment of Retinitis Pigmentosa

GenSight Biologics Reports its Cash Position as of September 30, 2018

GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to present REVERSE data with GS010 at the 2018 Annual Meeting of the American Academy of Ophthalmology